Novartis kidney cancer drug clears key hurdle
Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR Results of RECORD-1 trial address unmet medical need in renal cell cancer with worldwide regulatory filings planned for second half of 2008 Complete results to be submitted as late-breaking abstract for presentation at the American Society of Clinical Oncology meeting Basel, February 28, 2008 — An independent data monitoring committee stopped a major Phase III clinical trial of the investigational drug everolimus (RAD001) today after interim results showed significantly better progression-free survival in patients with advanced kidney cancer who received everolimus compared to placebo. The committee stopped the trial of more than 400 patients conducted in 12 countries because the study met its primary endpoint. The interim findings are being shared with investigators to allow them to offer everolimus to patients remaining on placebo. Everolimus may fulfill an unmet medical need for patients with advanced renal cell cancer (RCC) who currently have no approved treatment options. E...
As the nation’s opioid epidemic rages on, the federal agency charged with leading the government’s response to substance abuse is changing the way it helps local communities. But critics say the move risks leaving programs with fewer resources until the new plan is in place. The controversy began in January with a low-key announcement by the […]Related:E. coli outbreak spreads as source of tainted lettuce remains a mysteryFirst marijuana-derived drug poised for FDA approval after winning support from advisersHave you or someone you know waited too long for an organ transplant?
Conclusion: Our case report underlines the importance of active endoscopic surveillance of the remaining colon and rectum in patients with diverting stomas and inflammatory bowel disease in order to detect stenosis. If endoscopic control is not possible due to obliteration, surgical therapy must be discussed due to the risk of developing cancer.Case Rep Gastroenterol 2018;12:143 –146
Conclusions: This study is the first nationwide study presenting an increase in incidence of EP-NEC patients from 196 to 260 cases annually in the Netherlands. We found the best 5 year relative survival to be for EP-NEC patients with local disease located in the bladder, where the worst 5 year relative survival was found in the oesophagus.
Karine A. Al Feghali, Rami A. Ballout, Assem M. Khamis, Elie A. Akl, Fady B. Geara
Mayra A. Carrillo, Anjie Zhen, Scott G. Kitchen
Lisanne Lutter, Julia Spierings, Femke C. C. van Rhijn-Brouwer, Jacob M. van Laar, Femke van Wijk
PROSTATE cancer symptoms can be hard to spot, especially in the early stages. As it progresses, signs of the disease can begin to show, and if the cancer grows outside of the prostate, and other symptoms can develop, including three related to sex.
GIDEON what’s new summary: April 19 to April 20, 2018 Infectious Diseases – Outbreaks (8 updates) 8 DiseasesMap Infectious Diseases – Diseases (288 updates) 76 Clinical notes83 Diseases128 Country notes1 New Disease Synonym AddedMap Infectious Diseases – Drugs (2 updates) 2 Drugs Infectious Diseases – Vaccines (1 updates) 1 Vaccine The post Update: April 20, 2018 appeared first on GIDEON - Global Infectious Diseases and Epidemiology Online Network.
CONCLUSIONS Our results suggest that gastric cancer cells induce the transition of pericytes to CAFs by exosomes-mediated BMP transfer and PI3K/AKT and MEK/ERK pathway activation, and suggest that pericytes may be an important source of CAFs. PMID: 29668670 [PubMed - in process]
CONCLUSIONS This study is the first to provide evidence that propofol-mediated autophagy regulation is an underlying part of the mechanism by which propofol regulates HeLa cells progression. PMID: 29667627 [PubMed - in process]
More News: Avastin | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Cardiology | Clinical Trials | Government | Health | Heart | Heart Transplant | Kidney Cancer | Kidney Transplant | Kidney Transplantation | Lung Transplant | Lymphoma | Neurology | Oral Cancer | Pfizer | Renal Cell Carcinoma | Skin | Study | Transplant Surgery | Transplants | Tuberous Sclerosis | Urology & Nephrology | Vaccines